SecBot SecBot
8-K ·Filed Nov 5, 2026

IRTC

iRhythm Holdings, Inc.
MIXED
Impact 6/10
Horizonmonths Processed11d 11h ago SEC0001388658-26-000093
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The raised guidance and strong adjusted EBITDA margin expansion signal improving operational leverage, but the GAAP net loss widened significantly due to litigation settlements and acquisition costs. The VitalConnect acquisition adds a new revenue stream but also integration risk. Monitor the Q4 2026 earnings for the first full quarter of VitalConnect contribution and progress on margin targets.

DirectionMixed
Confidencehigh
Horizonmonths

Price Chart

Loading chart...

Executive Summary

iRhythm reported Q3 2026 revenue of $221.6M (+14.9% YoY), slightly below the $222.2M consensus, and GAAP net loss per share of -$0.90, well below the Street consensus of $0.02. Adjusted net income per diluted share was $0.82, reflecting strong operational leverage. The company raised FY 2026 revenue guidance to $890M-$895M and adjusted EBITDA margin guidance to 15.5%-16.0%, including the VitalConnect acquisition closed on October 5, 2026, and closed a new $300M revolving credit facility on November 3, 2026.

Key Financial Metrics

EPS
−$0.90
est $0.02 · -4600.0%
Revenue
$221.6M
est $222.2M · -0.3% · +14.9% YoY
Rating
miss
Guidance
$890M-$895M
raised
Free Cash Flow
-$11.5M
Gross Margin
74.2%

Key Facts

  • Q3 2026 revenue $221.6M, +14.9% YoY vs $192.9M, slightly below $222.2M consensus
  • GAAP net loss $29.9M ($0.90 per share) vs GAAP net loss $5.2M ($0.16) in Q3 2025
  • Adjusted net income $27.8M ($0.82 per diluted share) vs adjusted net loss $2.0M ($0.06) in Q3 2025
  • Gross margin 74.2%, up 310 bps YoY, including a $3.1M one-time tariff refund benefit
  • Adjusted EBITDA $51.2M (23.1% margin), up from $21.6M (11.2% margin) in Q3 2025
  • FY 2026 revenue guidance raised to $890M-$895M (from $875M-$885M), including ~$16M from VitalConnect
  • FY 2026 adjusted EBITDA margin guidance raised to 15.5%-16.0% (from 12.0%-13.0%)
  • Completed VitalConnect acquisition on October 5, 2026
  • Closed $300M senior secured revolving credit facility on November 3, 2026
  • GAAP operating expenses $197.0M included $49.8M in litigation settlements and $6.6M in business transformation costs
  • Free cash flow was negative $11.5M in Q3 2026 vs positive $20.1M in Q3 2025, partly due to $50.0M in Baxter patent litigation settlement payments

Financial Impact

Revenue $221.6M (+14.9% YoY), GAAP net loss $29.9M, adjusted net income $27.8M, guidance raised to $890M-$895M revenue and 15.5%-16.0% adjusted EBITDA margin

revenuenet incomeadjusted EBITDAguidancecash flow

Risk Factors

  • GAAP net loss widened to $29.9M from $5.2M in Q3 2025, driven by $49.8M in litigation settlements
  • Free cash flow turned negative $11.5M vs positive $20.1M a year ago, partly due to litigation payments
  • Revenue slightly missed consensus of $222.2M, though guidance was raised
  • Integration risk from the VitalConnect acquisition and associated business transformation costs
  • One-time tariff refund of $3.1M boosted gross margin; sustainability of margin expansion without such benefits is uncertain

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
95% bullish (22 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001388658-26-000093
Document: irtc-20261105.htm0001388658-26-000093
Document: 0001388658-26-000093-index-headers.html0001388658-26-000093
Document: 0001388658-26-000093-index.html0001388658-26-000093
Document: 0001388658-26-000093.txt0001388658-26-000093
8-K Data (Synthetic)0001388658-26-000093

Track record

31 reports on IRTC

Performance horizon

8 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +16.85% at T+60 after the Feb 25, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $90.12 Now $90.83 +0.79% settles Nov 23
  2. Nov 13, 20263d ago 8-K Neutral 2/10 Entry $91.91 Now $90.83 −1.18% settles Nov 20
  3. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $93.56 Now $90.83 −2.92% settles Nov 19
  4. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $93.56 Now $90.83 −2.92% settles Nov 19
  5. Nov 11, 20265d ago Press Release Neutral 3/10 Entry $93.56 Now $90.83 −2.92% settles Nov 19
  6. Nov 5, 202611d ago 8-K Mixed 6/10 Viewing No price data
  7. Nov 5, 202611d ago Press Release Bullish 6/10 Entry $90.22 to $91.91 Now $90.83 +0.68% ▲ +1.87% −0.72% vs SPY
  8. Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $123.99 to $134.00 Now $90.83 −26.74% ▲ +8.07% +8.79% vs SPY
  9. Oct 15, 20264w ago Press Release Neutral 1/10 Entry $108.66 Now $90.83 −16.41% No price data
  10. Oct 13, 20264w ago SC 13G/A Neutral 2/10 Entry $106.05 to $113.55 Now $90.83 −14.35% ▲ +7.07% +6.62% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens in 6h 9m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026